no data regarding the cost-effectiveness of antihypertensive drugs with regards to the development of diabetes can be found. Not just from a medical or economical but additionally from an ethical viewpoint, it’s debateable if it’s fair to treat patients Gemcitabine 122111-03-9 with diuretics and/or beta blockers if they’ve risk factors besides hypertension for developing diabetes mellitus. The anti-hypertensive therapy aims are avoiding cardiovascular mortality and cardiovascular events. The therapeutic benefit of the anti-hypertensive treatment has to be weighed against the danger of developing diabetes mellitus. Diabetes itself is also associated with a higher risk for cardio-vascular events and leads to death if left untreated. It remains to take care of patients at risk for cardiovascular events with drugs, which promote conditions which could again increase this risk. Could it be justifiable to treat hypertension and take the development of diabetesfi According to the recommendations Cholangiocarcinoma of the German Hypertension League and the German Society of Hypertension, diuretics and beta-blockers should not be prescribed for patients with metabolic syndrome or rather with different specific manifestations of the metabolic syndrome. Regarding appropriate elements, non-compliance of these guidelines may be viewed as a treatment error. The patient is able to prove the causality and a treatment error only occurs when the error leads to disability. This may be difficult, unless the individual was not informed properly regarding the possible danger of developing diabetes mellitus in the course of treatment with diuretics and/or beta blockers. While the incidence is higher for patients treated with diuretics or betablockers than for patients treated Bicalutamide price with calcium channelblockers, ACE inhibitors and ARB, conclusions/recommendations Anti-hypertensive treatment includes a important impact on the incidence of diabetes mellitus. This result is a lot stronger when both substance classes are employed in combination. The results of the identified publications in this report present a medically relevant limitation for the usage of diuretics and beta blockers. Patients with insulin resistent states, hypertension, disadvantaged plasmaglucose, obesity and heart failure should preferably be treated with ACE inhibitors and ARB. Further study is needed to verify the role of ACE inhibitors and ARB in preventing type 2 diabetes and to measure the risk for cardiovascular events and death because of drug induced diabetes. From the health economic point of view, evidence is lacking regarding the cost-effectiveness of the newer antihypertensive drugs in Germany. Predicated on costs for diabetes mellitus and its complications, the belief is made that using antihypertensive drugs, which result in a lower diabetes likelihood, may also be considered affordable for the German healthcare system.